Abstract
ADT is the main treatment for advanced prostate cancer. Combination therapy with radiotherapy in early stage prostate cancer is increasing. LHRH agonists are the most frequently used type of ADT for several years, and they have suppressed the serum testosterone to castration level in almost all patients. Furthermore, LHRH antagonist was developed recently as an alternative form of ADT with direct and immediate suppression of testosterone without initial testosterone flare phenomenon. Therefore, in this chapter, we will describe the comparative efficacy and safety between LHRH agonists and LHRH antagonists for prostate cancer.
| Original language | English |
|---|---|
| Title of host publication | Management of Advanced Prostate Cancer |
| Publisher | Springer Science+Business Media |
| Pages | 127-132 |
| Number of pages | 6 |
| ISBN (Electronic) | 9789811069437 |
| ISBN (Print) | 9789811069420 |
| DOIs | |
| State | Published - 1 Jan 2018 |
Bibliographical note
Publisher Copyright:© Springer Nature Singapore Pte Ltd. 2018.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Androgen deprivation therapy
- Gonadotropin-releasing hormone
- Prostate cancer
- Prostate-specific antigen
- Testosterone
Fingerprint
Dive into the research topics of 'LHRH Agonist and Antagonist for Prostate Cancer'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver